Study details
Enrolling now
Outpatient Treatment with Anti-Coronavirus Immunoglobulin Trial
University of Minnesota
NCT IDNCT04910269ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
820
Study length
about 5 years
Ages
18+
Locations
22 sites in AZ, CA, CO +10
About this study
This trial is testing whether a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) is better than a placebo for adults who have recently been diagnosed with COVID-19 and do not need hospitalization. The goal is to see if hIVIG helps people recover faster and improve their symptoms compared to the placebo.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Receive Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)
PhasePhase 3
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: All-cause hospitalization or death through 28 days., Healthcare Utilization at Follow-up
Body systems
Infectious